Krystal Biotech, Inc. (KRYS)
369.23
+5.39
(+1.48%)
USD |
NASDAQ |
Sep 02, 16:00
369.38
+0.15
(+0.04%)
After-Hours: 20:00
Krystal Biotech Research and Development Expense (TTM) : 53.39M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.39M |
| March 31, 2026 | 54.64M |
| December 31, 2025 | 55.08M |
| September 30, 2025 | 55.37M |
| June 30, 2025 | 55.70M |
| March 31, 2025 | 56.87M |
| December 31, 2024 | 53.57M |
| September 30, 2024 | 51.42M |
| June 30, 2024 | 48.54M |
| March 31, 2024 | 45.10M |
| December 31, 2023 | 46.43M |
| September 30, 2023 | 44.80M |
| June 30, 2023 | 45.02M |
| March 31, 2023 | 43.27M |
| December 31, 2022 | 39.84M |
| September 30, 2022 | 38.70M |
| June 30, 2022 | 33.46M |
| March 31, 2022 | 29.19M |
| December 31, 2021 | 26.10M |
| September 30, 2021 | 23.16M |
| Date | Value |
|---|---|
| June 30, 2021 | 22.65M |
| March 31, 2021 | 20.17M |
| December 31, 2020 | 17.94M |
| September 30, 2020 | 16.61M |
| June 30, 2020 | 15.40M |
| March 31, 2020 | 15.98M |
| December 31, 2019 | 15.62M |
| September 30, 2019 | 14.07M |
| June 30, 2019 | 12.10M |
| March 31, 2019 | 9.408M |
| December 31, 2018 | 7.761M |
| September 30, 2018 | 6.047M |
| June 30, 2018 | 5.488M |
| March 31, 2018 | 4.409M |
| December 31, 2017 | 3.208M |
| September 30, 2017 | 2.522M |
| June 30, 2017 | 1.408M |
| March 31, 2017 | 1.06M |
| December 31, 2016 | 0.741M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Marker Therapeutics, Inc. | 8.806M |
| TG Therapeutics, Inc. | 225.80M |
| Cytokinetics, Inc. | 384.41M |
| ADMA Biologics, Inc. | 11.52M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |